These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in …

Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …

Antipsychotic drugs (APDs) are best classified as typical or atypical. The distinction is based
solely on their ability to cause extrapyramidal side effects (EPS), including tardive dyskinesia …

OBJECTIVE: To assess the prevalence and correlates of antipsychotic polypharmacy (APP)
across decades and regions. METHODS: Electronic PubMed/Google Scholar search for …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

OBJECTIVE: The objectives of this study were to examine rates and predictors of
psychotropic use and multiclass polypharmacy among commercially insured children with …

Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a
high social cost. Depressed patients generally display co-morbid symptoms, and depression …

Context: Despite lacking evidence for its safety and efficacy, antipsychotic cotreatment is
common in schizophrenia. Objective: To evaluate therapeutic and adverse effects of …

OBJECTIVE: To determine whether the coprescribing of two or more antipsychotics, a
relatively frequent practice with little data to support its safety and efficacy, is associated with …

Antipsychotic polypharmacy refers to the co-prescription of more than one antipsychotic drug
for an individual patient. Surveys of prescribing in psychiatric services internationally have …